PDS Biotechnology Corp Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $144.50K, a 51.85% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $98.50K.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $531.09K.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $300.09K, a 80.81% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for fiscal 2021 was $344.13K.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for fiscal 2018 was $132.99K, a 12.52% increase from fiscal 2017.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for fiscal 2017 was $118.19K, a 59.80% decline from fiscal 2016.
- PDS Biotechnology Corp stock issued during period, value, stock options exercised for fiscal 2016 was $293.99K, a 26772.76% increase from fiscal 2015.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $144.50K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $98.50K 10-K · filed 2026-03-30 | |
| 2024-03-31 | $531.09K 10-K · filed 2026-03-30 | |
| 2023-12-31 | $300.09K 10-K · filed 2025-03-27 | |
| 2023-06-30 | $8.85K 10-K · filed 2025-03-27 | |
| 2022-12-31 | $1.56M 10-K · filed 2024-03-28 | |
| 2022-06-30 | $22.43K 10-K · filed 2024-03-28 | $153.44K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $7.49K 10-K · filed 2024-03-28 | $351.61K derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $13.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $344.13K 10-K · filed 2022-03-31 |
| 2021-09-30 | $123.51K 10-K · filed 2023-03-28 | |
| 2021-06-30 | $220.60K 10-K · filed 2023-03-28 | |
| 2018-12-31 | $107.58K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $132.99K 10-K · filed 2020-03-27 |
| 2018-09-30 | $25.41K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $118.19K 10-K · filed 2019-02-21 | |
| 2016-12-31 | $293.99K 10-K · filed 2018-03-01 | |
| 2015-12-31 | $1.09K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |